Novo CFO: Obesity market is difficult to predict

Although there is a market for weight loss treatments, and Novo Nordisk has already experienced huge demand for obesity drug Wegovy, the market still needs to be developed over coming years. For this reason, Novo Nordisk’s 2025 predictions are considerably lower than the analyst consensus.

Karsten Munk Knudsen, CFO of Novo Nordisk | Photo: Novo Nordisk / PR

While equity analysts predict that Novo Nordisk’s obesity drug sales will reach DKK 40bn (USD 5.9bn) in 2025, the company itself is only forecasting 2025 sales of ”over DKK 25bn (USD 3.7bn, ed.),” CFO Karsten Munk Knudsen tells Danish business daily Børsen.

No one doubts the market potential for weight loss treatments. Even so, a number of uncertainties make it difficult to predict where exactly Novo Nordisk will land in the future. These include the yet-to-be publicized crucial data on tirzepatide, a candidate from Novo Nordisk’s competitor Eli Lilly, and the fact that Wegovy still hasn’t been launched anywhere but the US.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs